In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...

Nestled in a prime location, this exceptional 5 bedroom house offers the perfect blend of spacious living and entrepreneurial potential. The property boasts a conveniently situated shop at the back, ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...

Barclays raised the firm’s price target on Sarepta (SRPT) to $209 from $203 and keeps an Overweight rating on the shares. The company reported a big Q3 beat on both total and Elevidys revenue ...

Cantor Fitzgerald analyst Kristen Kluska upgraded Sarepta (SRPT) to Overweight from Neutral with a price target of $167, up from $152. The company reported Q3 earnings, the first full quarter ...

“We want our clients to be in control of how they use the Zelta platform and so we do not set up services as a continuous revenue or cost drain, but instead we structure our services teams to deliver ...

(RTTNews) - Below are the earnings highlights for Sarepta Therapeutics (SRPT): Earnings: $33.6 million in Q3 vs. -$40.9 million in the same period last year. EPS: $0.34 in Q3 vs. -$0.46 in the ...

Sarepta Therapeutics (SRPT) reported $467.17 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 40.8%. EPS of $0.62 for the same period compares to ...